Skip to content
Phoenix Biotechnology, IncPhoenix Biotechnology, Inc
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us
Oleander

Phoenix Biotechnology acquires the assets of Anvirlat, Inc.

Posted on August 2003June 2022 by Carlos Torres
02
Aug

Phoenix Biotechnology acquires the assets of Anvirlat, Inc., a Nevada corporation, conducting pharmaceutical research in Central America on the therapeutic effects of plant extracts for patients suffering from neoplastic disease.

This entry was posted in Oleander. Bookmark the permalink.
Angel investor funding 2003
Technology Accelerator Initiative.
Copyright 2023 © Phoenix Biotechnology, Inc. All Rights Reserved. | Terms of Use | Privacy Policy | Cookies Policy
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us